Apps

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

IJR News — today's news from every side

Lilly Plans $2.88B Merida Autoimmune AcquisitionBusiness — 5dEli Lilly is rapidly expanding beyond its obesity-and-diabetes blockbuster lineup, striking two multi-deal paths: a $2.875 billion-plus acquisition of Merida Biosciences to broaden its autoimmune and antibody-directed therapies, and a $3.83 billion spree to acquire three biotech firms—Curevo, LimmaTech Biologics, and Vaccine Company—to build a broader vaccine and infectious-disease pipeline. The moves underscore a strategy to diversify growth into immunology, infectious diseases, and autoantibody therapies while managing revenue risk from reliance on a small number of weight‑loss drugs.

Lilly's $2.9B deal adds treatments for Graves' disease and food allergies — Aug 31, 2026Eli Lilly is acquiring Merida Biosciences for about $2.88 billion in cash, expanding its immunology and allergic-disease pipeline beyond its obesity drugs, with the deal expected to close in Q4 2026 and marking Lilly’s ongoing aggressive M&A strategy. Merida’s lead program MER511 targets Graves’ disease and thyroid eye disease, while MER769 is in preclinical development for food allergy, asthma and chronic spontaneous urticaria, underscoring a broadened portfolio as Lilly references roughly $29 billion in upfront and milestone payments this year across acquisitions.